629 related articles for article (PubMed ID: 17299061)
1. Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women.
Wachs DS; Coffler MS; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2007 May; 92(5):1871-4. PubMed ID: 17299061
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
3. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
4. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Codner E; Maliqueo M; Echiburú B; Hitschfeld C; Crisosto N; Pérez-Bravo F; Recabarren SE; Cassorla F
J Clin Endocrinol Metab; 2006 Aug; 91(8):3105-9. PubMed ID: 16720659
[TBL] [Abstract][Full Text] [Related]
5. Comparison of follicle-stimulating-hormone-stimulated dimeric inhibin and estradiol responses as indicators of granulosa cell function in polycystic ovary syndrome and normal women.
Wachs DS; Coffler MS; Malcom PJ; Chang RJ
J Clin Endocrinol Metab; 2006 Aug; 91(8):2920-5. PubMed ID: 16720653
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.
Pigny P; Jonard S; Robert Y; Dewailly D
J Clin Endocrinol Metab; 2006 Mar; 91(3):941-5. PubMed ID: 16368745
[TBL] [Abstract][Full Text] [Related]
7. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
Pierre A; Peigné M; Grynberg M; Arouche N; Taieb J; Hesters L; Gonzalès J; Picard JY; Dewailly D; Fanchin R; Catteau-Jonard S; di Clemente N
Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
[TBL] [Abstract][Full Text] [Related]
8. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.
Laven JS; Mulders AG; Visser JA; Themmen AP; De Jong FH; Fauser BC
J Clin Endocrinol Metab; 2004 Jan; 89(1):318-23. PubMed ID: 14715867
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.
Pigny P; Merlen E; Robert Y; Cortet-Rudelli C; Decanter C; Jonard S; Dewailly D
J Clin Endocrinol Metab; 2003 Dec; 88(12):5957-62. PubMed ID: 14671196
[TBL] [Abstract][Full Text] [Related]
10. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries.
Pellatt L; Hanna L; Brincat M; Galea R; Brain H; Whitehead S; Mason H
J Clin Endocrinol Metab; 2007 Jan; 92(1):240-5. PubMed ID: 17062765
[TBL] [Abstract][Full Text] [Related]
11. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
[TBL] [Abstract][Full Text] [Related]
12. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome.
Lie Fong S; Schipper I; de Jong FH; Themmen AP; Visser JA; Laven JS
Fertil Steril; 2011 Aug; 96(2):459-63. PubMed ID: 21719005
[TBL] [Abstract][Full Text] [Related]
13. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome.
Coffler MS; Patel K; Dahan MH; Malcom PJ; Kawashima T; Deutsch R; Chang RJ
J Clin Endocrinol Metab; 2003 Apr; 88(4):1742-7. PubMed ID: 12679467
[TBL] [Abstract][Full Text] [Related]
14. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
Sahmay S; Atakul N; Aydogan B; Aydin Y; Imamoglu M; Seyisoglu H
Acta Obstet Gynecol Scand; 2013 Dec; 92(12):1369-74. PubMed ID: 23980726
[TBL] [Abstract][Full Text] [Related]
16. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.
Guedikian AA; Lee AY; Grogan TR; Abbott DH; Largaespada K; Chazenbalk GD; Dumesic DA
Fertil Steril; 2018 Mar; 109(3):508-515. PubMed ID: 29428312
[TBL] [Abstract][Full Text] [Related]
17. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study.
Homburg R; Ray A; Bhide P; Gudi A; Shah A; Timms P; Grayson K
Hum Reprod; 2013 Apr; 28(4):1077-83. PubMed ID: 23377771
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ
Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152
[TBL] [Abstract][Full Text] [Related]
19. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
[TBL] [Abstract][Full Text] [Related]
20. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.
Catteau-Jonard S; Pigny P; Reyss AC; Decanter C; Poncelet E; Dewailly D
J Clin Endocrinol Metab; 2007 Nov; 92(11):4138-43. PubMed ID: 17698904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
